The Effects of Ronacaleret, a Calcium-Sensing Receptor Antagonist, on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Women with Low Bone Mineral Density | Zendy

Lorraine A. Fitzpatrick | Zendy; Christine Dabrowski | Zendy; Greg Cicconetti | Zendy; David N. Gordon | Zendy; Socrates E. Papapoulos | Zendy; Henry G. Bone | Zendy; John P. Bilezikian | Zendy

Open Access

The Effects of Ronacaleret, a Calcium-Sensing Receptor Antagonist, on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Women with Low Bone Mineral Density

Author(s) -

Lorraine A. Fitzpatrick,

Christine Dabrowski,

Greg Cicconetti,

David N. Gordon,

Socrates E. Papapoulos,

Henry G. Bone,

John P. Bilezikian

Publication year - 2011

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2010-2855

Subject(s) - teriparatide , bone mineral , bone remodeling , medicine , femoral neck , endocrinology , osteoporosis , urology , bone density , placebo , alternative medicine , pathology

Ronacaleret, a calcium-sensing receptor antagonist that stimulates PTH release from the parathyroid glands, was evaluated as an oral osteoanabolic agent for the treatment of osteoporosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research